Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-NYM158
- Development stage
- Preclinical
- Lead developer
- Norroy Bioscience
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
177Lu-NYM158 is an investigational, antagonist-based radiopharmaceutical candidate developed by Norroy Bioscience for the treatment of aggressive neuroendocrine neoplasms and small cell lung cancer. The therapeutic agent consists of the beta-emitting radionuclide lutetium-177 (177Lu) conjugated to NYM158, a targeting ligand that selectively binds to somatostatin receptor type 2 (SSTR2). SSTR2 is a G-protein coupled receptor overexpressed in various solid tumors. By acting as an antagonist, 177Lu-NYM158 binds to SSTR2 on the surface of tumor cells, delivering targeted ionizing radiation directly to the cancer cells to induce DNA damage and cell death. It is currently in preclinical development.
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on 177Lu-NYM158.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-NYM158.